バーテックス・ファーマシューティカルズ (Japanese Wikipedia)

{{Cite journal|last=|date=August 2016|title=Vertex, Moderna Launch Cystic Fibrosis Collaboration|url=http://www.genengnews.com/gen-news-highlights/vertex-moderna-launch-cystic-fibrosis-collaboration/81252914/%7Cjournal=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News|volume=36|issue=14|page=17|department=News: Discovery & Development|type=Paper}}

ghostarchive.org

“Voices Carry: How History Informs Patient Advocacy in the Biotech Industry”. YouTube (14 May 2014). 2021年12月13日時点のオリジナルよりアーカイブ。3 July 2019閲覧。

google.co.jp

books.google.co.jp

Werth, Barry (1994). The Billion-Dollar Molecule: One Company's Quest for the Perfect Drug. New York: Simon & Schuster. ISBN 0671510576. OCLC 32047662 The Billion-Dollar Molecule - Google ブックス.

hoovers.com

“Vertex Pharmaceuticals Incorporated”. Hoover's. 24 June 2012閲覧。

hsj.co.uk

“NHS England finally strikes deal for high value drug”. Health Service Journal. (24 October 2019) 3 December 2019閲覧。

kalydeco.com

“KALYDECO™ (ivacaftor) tablets”. Vertex Pharmaceuticals. 24 June 2012閲覧。

marketwatch.com

Owens, Jeremy C. (23 January 2019). “Vertex terminates COO for 'personal behavior'”. MarketWatch 25 January 2019閲覧。

medpagetoday.com

John Fauber (19 May 2013). “Cystic Fibrosis: Charity and Industry Partner for Profit”. MedPage Today, Milwaukee Journal Sentinel. 19 July 2015閲覧。
David M. Orenstein; Paul M. Quinton; Brian P. O'Sullivan; Carlos E. Milla; Mark Pian (9 July 2012), Letter to Jeff Leiden, CEO of Vertex Pharmaceuticals 19 July 2015閲覧。

nasdaq.com

“Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics”. nasdaq.com (4 September 2021). 12 September 2021閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

Deborah Cohen; James Raftery (12 February 2014). “Orphan Drugs: Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding”. BMJ 348: g1445. doi:10.1136/bmj.g1445. PMID 24523379.

nytimes.com

patientsforaffordabledrugs.org

“The problem is the price: 5 reasons the cystic fibrosis community and its allies must band together to speak out about our drug prices – right now.”. Patients For Affordable Drugs (17 May 2018). 3 February 2019閲覧。

pmlive.com

Parsons, Lucy (2019年10月24日). “Vertex, NHS England and NICE finally reach agreement for Orkambi” (英語). PMLive. 2019年10月29日閲覧。 “The triple therapy, which has just received approval from the FDA in the US, is thought to be effective in up to 90% of CF patients.”
Parsons, Lucy (2019年10月24日). “Vertex, NHS England and NICE finally reach agreement for Orkambi” (英語). PMLive. 2019年10月29日閲覧。 “The triple therapy, which has just received approval from the FDA in the US, is thought to be effective in up to 90% of CF patients.”

reuters.com

uk.reuters.com

“Vertex to buy cell therapy developer Semma for $950 million” (3 September 2019). 2020年7月9日閲覧。

sec.gov

“Vertex Pharmaceuticals Inc. 2022 Annual Report (Form 10-K)”. U.S. Securities and Exchange Commission (February 10, 2023). 2023年9月19日閲覧。

statnews.com

“Vertex Pharmaceuticals' Jeffrey Leiden to step aside as CEO” (英語). STAT (25 July 2019). 31 July 2019閲覧。
Silverman, Ed (2019年10月24日). “Vertex and the U.K. reach a deal for cystic fibrosis medicines” (英語). STAT. 2019年10月29日閲覧。

theguardian.com

Boseley, Sarah (3 February 2019). “Cystic fibrosis: the patients facing shorter lives due to drug's expense” (英語). The Guardian. ISSN 0261-3077 3 February 2019閲覧。
Boseley, Sarah (27 March 2019). “600 years' supply of cystic fibrosis drug destroyed in price row”. the Guardian. 29 March 2019閲覧。

time.com

Time Staff. “12 Innovations That Will Change Health Care and Medicine in the 2020s”. Time 29 October 2019閲覧。.

vrtx.com

investors.vrtx.com

“Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance” (英語). Vertex Pharmaceuticals. 30 May 2019閲覧。
“Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation | Vertex Pharmaceuticals”. investors.vrtx.com. 2020年7月9日閲覧。
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies, PM Vertex May 11, 2020; retrieved May 11, 2020

vrtx.com

“VX-809 (Cystic Fibrosis)”. Vertex Pharmaceuticals (7 September 2011). 24 June 2012閲覧。
“Pipeline | Vertex Pharmaceuticals”. www.vrtx.com. 2020年7月9日閲覧。

washingtonpost.com

Brady Dennis (2 July 2015), “Are risks worth the rewards when nonprofits act like venture capitalists?”, The Washington Post 19 July 2015閲覧。

web.archive.org

“Voices Carry: How History Informs Patient Advocacy in the Biotech Industry”, Life Sciences Foundation (Cambridge, Massachusetts), (15 April 2015), オリジナルの7 March 2016時点におけるアーカイブ。 19 July 2015閲覧。

worldcat.org

search.worldcat.org

worldcat.org

Werth, Barry (1994). The Billion-Dollar Molecule: One Company's Quest for the Perfect Drug. New York: Simon & Schuster. ISBN 0671510576. OCLC 32047662 The Billion-Dollar Molecule - Google ブックス.
Werth, Barry (2014). The Antidote: Inside the World of New Pharma. New York: Simon & Schuster. ISBN 9781451655667. OCLC 859375019

wsj.com

blogs.wsj.com

“From Riches to Rags: Vertex Discontinues Incivek as Sales Evaporate”. Pharmalot. Dow Jones & Company (August 12, 2014). August 13, 2014閲覧。

xconomy.com

“Xconomy: Vertex Seeks FDA Green Light for Cystic Fibrosis Drug, Second Potential Hit of Big Year” (英語). Xconomy (19 October 2011). 10 June 2019閲覧。
“Vertex, CRISPR Tx Team up on Gene Editing Drugs in $105M Pact”. Exome (26 October 2015). 2022年7月9日閲覧。

youtube.com

“Voices Carry: How History Informs Patient Advocacy in the Biotech Industry”. YouTube (14 May 2014). 2021年12月13日時点のオリジナルよりアーカイブ。3 July 2019閲覧。